公开(公告)号：US12227569B2

公开(公告)日：2025-02-18

申请号：US17376314

申请日：2021-07-15

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Nicolas Schneider

IPC: C07K16/28 ,  A61K9/00 ,  A61K39/00 ,  A61K39/395 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  C07K16/30

Abstract: The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.

公开(公告)号：US12195555B2

公开(公告)日：2025-01-14

申请号：US18469947

申请日：2023-09-19

Applicant: SANOFI ,  INNATE PHARMA

Inventor： Nicolas Gourdin ,  Laurent Gauthier ,  Alexandre Tang ,  Marielle Chiron ,  Angela Virone-Oddos ,  Alessandro Masiero ,  Jochen Beninga ,  Ingo Focken ,  Sambasiva Rao ,  Yanfeng Zhou ,  Leila Sevigny

IPC: C07K16/46 ,  A61P35/00 ,  C12N15/63

Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human BCMA and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof bind to a human Fc-γ receptor.
The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including multiple myeloma (MM).

公开(公告)号：US20240392008A1

公开(公告)日：2024-11-28

申请号：US18568310

申请日：2022-06-08

Applicant: INNATE PHARMA

Inventor： Laurent GAUTHIER ,  Yannis MOREL ,  Olivier DEMARIA

IPC: C07K16/28 ,  A61K38/00 ,  C07K14/55

Abstract: Multispecific proteins that bind NKp46 and specifically redirect effector cells to lyse a target cell of interest via multiple receptors are provided. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US20240391999A1

公开(公告)日：2024-11-28

申请号：US18648579

申请日：2024-04-29

Applicant: INNATE PHARMA

Inventor： CARINE PATUREL ,  HELENE SICARD

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K16/30

Abstract: This invention relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.

公开(公告)号：US20240294634A1

公开(公告)日：2024-09-05

申请号：US17768484

申请日：2020-10-13

Applicant: INNATE PHARMA

Inventor： OLIVIER BENAC ,  STÉPHANIE CHANTEUX ,  IVAN PERROT ,  BENJAMIN ROSSI ,  NICOLAS VIAUD

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61P35/00 ,  A61K2039/507

Abstract: This invention relates to the use of a NKG2A-neutralizing agent and an antibody that inhibits human ILT2 to treat cancer, particularly a head and neck squamous cell carcinoma (HNSCC), a lung cancer, optionally an NSCLC, a renal cell carcinoma, a colorectal carcinoma, a urothelial cancer or an ovarian cancer.

公开(公告)号：US20240270865A1

公开(公告)日：2024-08-15

申请号：US18020955

申请日：2021-08-06

Applicant: INNATE PHARMA

Inventor： LAURENT GAUTHIER ,  CARINE PATUREL ,  IVAN PERROT

IPC: C07K16/28 ,  A61K31/337 ,  A61K39/00 ,  A61P35/00 ,  C07K16/32

CPC classification number: C07K16/2896 ,  A61K31/337 ,  A61P35/00 ,  C07K16/32 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/76

Abstract: The disclosure relates to methods and compositions for the treatment of cancer. Specifically, the disclosure relates to methods for administering anti-CD73 antibodies, and to methods for using anti-CD73 antibodies for the treatment of cancers, preferably HER2-positive gastric adenocarcinoma or a gastroesophageal junction adenocarcinoma in an individual.

公开(公告)号：US11999784B2

公开(公告)日：2024-06-04

申请号：US16451051

申请日：2019-06-25

Applicant: INNATE PHARMA

Inventor： Cécile Bonnafous ,  Hélène Sicard ,  Renaud Buffet ,  Mathieu Blery

IPC: C07K16/28 ,  C07K16/30 ,  G01N33/574

CPC classification number: C07K16/28 ,  C07K16/2803 ,  C07K16/3061 ,  G01N33/57407 ,  C07K2317/73 ,  C07K2317/732 ,  G01N2333/70503

Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.

公开(公告)号：US20240124579A1

公开(公告)日：2024-04-18

申请号：US18396776

申请日：2023-12-27

Applicant: INNATE PHARMA

Inventor： LAURENT GAUTHIER ,  SIMON KOLLNBERGER ,  BENJAMIN ROSSI ,  HÉLÈNE SICARD ,  CARINE PATUREL ,  STÉPHANIE CORNEN ,  STÉPHANIE ZERBIB

IPC: C07K16/28 ,  G01N33/569

CPC classification number: C07K16/2803 ,  G01N33/56966 ,  G01N33/56972 ,  A61K2039/505 ,  G01N2800/7095

Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.

公开(公告)号：US11572410B2

公开(公告)日：2023-02-07

申请号：US16924288

申请日：2020-07-09

Applicant: INNATE PHARMA

Inventor： Pascale Andre ,  Mathieu Blery ,  Carine Paturel ,  Nicolai Wagtmann

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00

Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.

公开(公告)号：US11267897B2

公开(公告)日：2022-03-08

申请号：US16173114

申请日：2018-10-29

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Nadia Anceriz ,  Ariane Morel ,  Benjamin Rossi

IPC: A61P43/00 ,  C07K16/28 ,  C12N15/62

Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.